Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 12,100 shares, a decline of 24.8% from the May 15th total of 16,100 shares. Based on an average daily trading volume, of 526,600 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.7% of the shares of the stock are sold short.

Lixte Biotechnology Stock Down 2.8 %

Shares of NASDAQ LIXT traded down $0.07 during midday trading on Friday, reaching $2.45. 1,148,787 shares of the company were exchanged, compared to its average volume of 28,170. Lixte Biotechnology has a one year low of $1.58 and a one year high of $9.50. The stock has a market cap of $5.51 million, a P/E ratio of -1.05 and a beta of -0.21. The stock’s 50-day moving average price is $2.79 and its 200-day moving average price is $2.52.

Lixte Biotechnology (NASDAQ:LIXT) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.43) EPS for the quarter.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.